Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PF-06865571 Immediate release · 1 trial · 1 indication
Time to Reach Maximum Observed Plasma Concentration (Tmax)
Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast)
AUC (0-infinity)= Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0-infinity). It is obtained from AUC (0-t) plus AUC (t-infinity).
Plasma Decay Half-Life (t1/2)
| Arm | Type | Description |
|---|---|---|
| PF-06865571 | EXPERIMENTAL | Treatment |
| Name | Type | Description |
|---|---|---|
| PF-06865571 Immediate release suspension | DRUG | Suspension |
| PF-06865571 Slow release MR tablets | DRUG | Modified release tablets |
| PF-06865571 Fast release MR tablets | DRUG | Modified release tablets |
| PF-06865571 Immediate release tablets | DRUG | Immediate release tablets |
Inclusion Criteria: * Healthy males and female of non-childbearing potential * Age of 18-55, inclusive * Body Mass Index 17.5 to 30.5 kg/m2, inclusive * Body weight \>50 kg * Not on any prescription or non-prescription drugs within 7 days or 5 half-lives prior to first dose. Exclusion Criteria: *...
PF-06865571 Immediate release is an investigational small molecule being studied in healthy subjects. It is currently in Phase 1 clinical development, with a completed trial evaluating different formulations of the drug in healthy volunteers.
PF-06865571 Immediate release is being developed by Pfizer, Inc., a biopharmaceutical company listed on the New York Stock Exchange under the ticker symbol PFE.
PF-06865571 Immediate release is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still being studied in clinical trials.
PF-06865571 Immediate release has one completed clinical trial, NCT03372044, titled "A Study To Evaluate Different Formulations Of PF-06865571 In Healthy Subjects." This Phase 1 trial enrolled 12 healthy participants in Belgium and was not blinded or controlled.
PF-06865571 Immediate release is a specific formulation of the drug PF-06865571. The clinical trial NCT03372044 was designed to evaluate different formulations of PF-06865571, including the immediate release version, in healthy subjects.